SKIP TO CONTENT
Johns Hopkins
  • Home
  • About
  • News
  • Contact
  • Login

    • FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

    FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

    A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center.

    LEARN MORE
    SEE ALL NEWS
    Recent Posts
    Prostate Cancer: Advancements in Screening Experimental KRAS Vaccine Generates Immune Response Against Pancreatic Cancer in People at High Risk Newly Identified Inhibitors May Boost Chemotherapy Drug’s Ability to Fight Treatment-Resistant Cancers Virtual Tumor Predict Response to Liver Cancer Immunotherapy Ovarian Cancer Researcher Wins Prestigious Lotus Award Blocking Energy Metabolism May Help Treat Aggressive Pediatric Brain Tumor This new drug could change how we treat one of the deadliest cancers Inherited Long Telomeres May Drive Broad Risk for Lymphoid Cancers How a Division I athlete who never smoked turned his stage 4 ALK+ lung cancer diagnosis into a fight for a cure
    Johns Hopkins

    2026 © The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
    Terms of Use Privacy Statement

    LinkedIn
    Back to top